scholarly journals Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Shou-Sheng Liu ◽  
Xue-Feng Ma ◽  
Jie Zhao ◽  
Shui-Xian Du ◽  
Jie Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Gastric Cancer ◽  
Observational Studies ◽  
Pancreas Cancer ◽  
Colorectal Adenomas ◽  
Cochrane Library ◽  
Extrahepatic Cholangiocarcinoma ◽  
Esophagus Cancer ◽  
Cancer Prostate

Abstract Background NAFLD was tightly associated with various diseases such as diabetes, cardiovascular disease, kidney disease and cancer. Previous studies had investigated the association between NAFLD and various extrahepatic cancers, but the conclusions were remains to be improved. The aim of this study was to investigate the association between NAFLD and various extrahepatic cancer comprehensively. Methods Electronic databases PubMed, EMBASE, Medline, and the Cochrane Library were searched for observational studies published from 1996 to January 2020. Observational studies that reflected the association between NAFLD and extrahepatic cancers were included in this study. The pooled OR/HR/IRR of the association between NAFLD and various extrahepatic cancers were analyzed. Results A total of 26 studies were included for investigating the association between NAFLD and various extrahepatic cancers. As the result shown, the pooled OR values of the risk of colorectal cancer and adenomas in patients with NAFLD were 1.72 (95%CI: 1.40-2.11) and 1.38 (95%CI: 1.22-1.56), respectively. The pooled OR values of the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in patients with NAFLD were 2.40 (95%CI: 1.75-3.31) and 2.24 (95%CI: 1.58-3.17), respectively. The pooled OR value of the risk of breast cancer in patients with NAFLD was 1.68 (95%CI: 1.44-1.97). In addition, NAFLD was also tightly associatied with the risk of gastric cancer, pancreas cancer, prostate cancer, and esophagus cancer. Conclusions NAFLD could significantly increase the development risk of colorectal adenomas and cancer, intrahepatic and extrahepatic cholangiocarcinoma, breast cancer, gastric cancer, pancreas cancer, prostate cancer, and esophagus cancer.

scholarly journals Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Shou-Sheng Liu ◽  
Xue-Feng Ma ◽  
Jie Zhao ◽  
Shui-Xian Du ◽  
Jie Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Gastric Cancer ◽  
Pancreatic Cancer ◽  
Colorectal Adenomas ◽  
Cochrane Library ◽  
Extrahepatic Cholangiocarcinoma ◽  
Nonalcoholic Fatty Liver ◽  
Esophagus Cancer ◽  
Cancer Prostate

Abstract Background: NAFLD is tightly associated with various diseases such as diabetes, cardiovascular disease, kidney disease, and cancer. Previous studies had investigated the association between NAFLD and various extrahepatic cancers, but the available data to date is not conclusive. The aim of this study was to investigate the association between NAFLD and various extrahepatic cancers comprehensively. Methods: Searches were conducted of various electronic databases (PubMed, EMBASE, Medline, and the Cochrane Library) to identify observational studies published between 1996 and January 2020 which investigated the association between NAFLD and extrahepatic cancers. The pooled OR/HR/IRR of the association between NAFLD and various extrahepatic cancers were analyzed. Results: A total of 26 studies were included to investigate the association between NAFLD and various extrahepatic cancers. As the results shown, the pooled OR values of the risk of colorectal cancer and adenomas in patients with NAFLD were 1.72 (95%CI: 1.40-2.11) and 1.38 (95%CI: 1.22-1.56), respectively. The pooled OR values of the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in patients with NAFLD were 2.40 (95%CI: 1.75-3.31) and 2.24 (95%CI: 1.58-3.17), respectively. The pooled OR value of the risk of breast cancer in patients with NAFLD was 1.68 (95%CI: 1.44-1.97). In addition, NAFLD was also tightly associatied with the risk of gastric cancer, pancreatic cancer, prostate cancer, and esophagus cancer. Conclusions: NAFLD could significantly increase the development risk of colorectal adenomas and cancer, intrahepatic and extrahepatic cholangiocarcinoma, breast cancer, gastric cancer, pancreatic cancer, prostate cancer, and esophagus cancer.

scholarly journals Association between nonalcoholic fatty liver disease and extrahepatic cancers: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Shou-Sheng Liu ◽  
Xue-Feng Ma ◽  
Jie Zhao ◽  
Shui-Xian Du ◽  
Jie Zhang ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Fatty Liver Disease ◽  
Observational Studies ◽  
Meta Analysis ◽  
Colorectal Adenomas ◽  
Cochrane Library ◽  
Extrahepatic Cholangiocarcinoma ◽  
Nonalcoholic Fatty Liver ◽  
The Cochrane Library ◽  
Development Risk

Abstract Background NAFLD is tightly associated with various diseases such as diabetes, cardiovascular disease, kidney disease, and cancer. Previous studies had investigated the association between NAFLD and various extrahepatic cancers, but the available data to date is not conclusive. The aim of this study was to investigate the association between NAFLD and various extrahepatic cancers comprehensively. Methods Searches were conducted of various electronic databases (PubMed, EMBASE, Medline, and the Cochrane Library) to identify observational studies published between 1996 and January 2020 which investigated the association between NAFLD and extrahepatic cancers. The pooled OR/HR/IRR of the association between NAFLD and various extrahepatic cancers were analyzed. Results A total of 26 studies were included to investigate the association between NAFLD and various extrahepatic cancers. As the results shown, the pooled OR values of the risk of colorectal cancer and adenomas in patients with NAFLD were 1.72 (95%CI: 1.40-2.11) and 1.37 (95%CI: 1.29-1.46), respectively. The pooled OR values of the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in patients with NAFLD were 2.46 (95%CI: 1.77-3.44) and 2.24 (95%CI: 1.58-3.17), respectively. The pooled OR value of the risk of breast cancer in patients with NAFLD was 1.69 (95%CI: 1.44-1.99). In addition, NAFLD was also tightly associated with the risk of gastric cancer, pancreatic cancer, prostate cancer, and esophageal cancer. Conclusions NAFLD could significantly increase the development risk of colorectal adenomas and cancer, intrahepatic and extrahepatic cholangiocarcinoma, breast, gastric, pancreatic, prostate, and esophageal cancer. NAFLD could be considered as one of the influencing factors during the clinical diagnosis and treatment for the extrahepatic cancers.

scholarly journals Association between nonalcoholic fatty liver disease and extrahepatic cancers: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Shou-Sheng Liu ◽  
Xue-Feng Ma ◽  
Jie Zhao ◽  
Shui-Xian Du ◽  
Jie Zhang ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Fatty Liver Disease ◽  
Observational Studies ◽  
Meta Analysis ◽  
Colorectal Adenomas ◽  
Cochrane Library ◽  
Extrahepatic Cholangiocarcinoma ◽  
Nonalcoholic Fatty Liver ◽  
The Cochrane Library ◽  
Development Risk

Abstract Background NAFLD is tightly associated with various diseases such as diabetes, cardiovascular disease, kidney disease, and cancer. Previous studies had investigated the association between NAFLD and various extrahepatic cancers, but the available data to date is not conclusive. The aim of this study was to investigate the association between NAFLD and various extrahepatic cancers comprehensively. Methods Searches were conducted of various electronic databases (PubMed, EMBASE, Medline, and the Cochrane Library) to identify observational studies published between 1996 and January 2020 which investigated the association between NAFLD and extrahepatic cancers. The pooled OR/HR/IRR of the association between NAFLD and various extrahepatic cancers were analyzed. Results A total of 26 studies were included to investigate the association between NAFLD and various extrahepatic cancers. As the results shown, the pooled OR values of the risk of colorectal cancer and adenomas in patients with NAFLD were 1.72 (95%CI: 1.40-2.11) and 1.37 (95%CI: 1.29-1.46), respectively. The pooled OR values of the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in patients with NAFLD were 2.46 (95%CI: 1.77-3.44) and 2.24 (95%CI: 1.58-3.17), respectively. The pooled OR value of the risk of breast cancer in patients with NAFLD was 1.69 (95%CI: 1.44-1.99). In addition, NAFLD was also tightly associated with the risk of gastric cancer, pancreatic cancer, prostate cancer, and esophageal cancer. Conclusions NAFLD could significantly increase the development risk of colorectal adenomas and cancer, intrahepatic and extrahepatic cholangiocarcinoma, breast, gastric, pancreatic, prostate, and esophageal cancer. NAFLD could be considered as one of the influencing factors during the clinical diagnosis and treatment for the extrahepatic cancers.

scholarly journals Cancers in Togo from 1984 to 2008: Epidemiological and Pathological Aspects of 5251 Cases

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Koffi Amégbor ◽  
Tchin Darre ◽  
Koffi Didier Ayéna ◽  
Essohana Padaro ◽  
Kodjo Tengué ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Gastric Cancer ◽  
Skin Cancer ◽  
Sex Ratio ◽  
Average Frequency ◽  
Pathological Features ◽  
Annual Average ◽  
Cancer Register ◽  
Non Hodgkin Lymphoma

Objective. To describe the epidemiological and histological aspects of cancers in Togo.Materials and Methods. We made a retrospective review of the epidemiological and pathological features of cancers observed from 1984 to 2008 at the laboratory of pathology of CHU-TOKOIN in Lomé, Togo.Results. During our study period, we found 5251 cases of cancers with an annual average frequency of 210 cases. The sex ratio, male/female, was 0.9 and the average age of occurring was 45.3 years. This average age was 46.9 years for men and 43.8 years for women. The most frequent cancers for men were prostate cancer (12.9%), nonmelanoma skin cancer (10.4%), and gastric cancer (10.3%). For women it was breast cancer (27.1%), cervix cancer (11.2%) and non-Hodgkin lymphoma (6.3%). Histologically, it was carcinomas in 68.1% of the cases, sarcomas in 11% of the cases and non-Hodgkin lymphomas in 12.6% of the cases. Children cancers were primarily Burkitt lymphoma (27.9% of cases) and retinoblastoma (8.5% of cases).Conclusion. This study shows that cancers are frequent in Togo and emphasizes on the necessity of having a cancer register for the prevention and the control of this disease in Togo.

Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy

2004 ◽  
Vol 9 (6) ◽  
pp. 687-695 ◽  
Author(s):  
Charles L. Vogel ◽  
Ronald H. Yanagihara ◽  
Albert J. Wood ◽  
Frederick M. Schnell ◽  
Charles Henderson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Multiple Myeloma ◽  
Zoledronic Acid ◽  
Bisphosphonate Therapy ◽  
Pain Palliation ◽  
Cancer Prostate

Second primary malignancies in gastric cancer: A U.S. population-based study.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 191-191
Author(s):  
Binay Kumar Shah ◽  
Amit Khanal
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Gastric Cancer ◽  
Thyroid Cancer ◽  
Myeloid Leukemia ◽  
Population Based ◽  
Second Primary ◽  
Population Based Study ◽  
Gastrointestinal Malignancies ◽  
Second Primary Malignancies

191 Background: Risk of second primary malignancies (SPM) is not known in gastric cancer. In this population based study, we analyzed rates of SPM in gastric cancer. Methods: We selected adult (≥18 years) patients with gastric cancer as first primary malignancy diagnosed from January 1992 to December 2011 from Surveillance, Epidemiology and End Result 13 database. We used SEER*stat’s multiple primary standardized incidence ratio (MP-SIR) session to calculate the risk of SPM diagnosed 6 months after the diagnosis of index gastric cancer. Results: Among 31,818 patients with first primary gastric cancer, 1674 (5.26%) developed 1,839 SPM with observed/expected (O/E) ratio of 1.09 (95% CI = 1.05-1.15, p<0.0001) and excess risk of 16.15 per 10,000 population. The median time to first SPM from the time of diagnosis of stomach cancer was 49 months (range 6 months to 19.08 years). There was significantly increased risk of gastrointestinal malignancies [O/E ratio 1.65 (CI=1.53-1.79, p<0.001)], thyroid cancer [O/E ratio 1.98 (CI=1.32-2.84, p<0.01)] and myeloid leukemia [O/E ratio 1.47(CI=1-2.09, p<0.05)]. Interestingly, there was significantly decreased risk of melanoma, breast cancer and prostate cancer. Conclusions: Our study showed that patients with gastric cancer are at higher risk of gastrointestinal malignancies, thyroid cancer and myeloid leukemia. Similarly, risk of melanoma, breast cancer and prostate cancer in patients with gastric cancer is lower than general population.

scholarly journals Association between aberrant APC promoter methylation and breast cancer pathogenesis: a meta-analysis of 35 observational studies

PeerJ ◽  
2016 ◽  
Vol 4 ◽  
pp. e2203 ◽  
Author(s):  
Dan Zhou ◽  
Weiwei Tang ◽  
Wenyi Wang ◽  
Xiaoyan Pan ◽  
Han-Xiang An ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Studies ◽  
Meta Analysis ◽  
Random Effect ◽  
Random Effect Model ◽  
Wnt Signaling Pathway ◽  
Detection Methods ◽  
Cochrane Library ◽  
Cancer Pathogenesis ◽  
Potential Biomarker

Background.Adenomatous polyposis coli (APC) is widely known as an antagonist of the Wnt signaling pathway via the inactivation ofβ-catenin. An increasing number of studies have reported that APC methylation contributes to the predisposition to breast cancer (BC). However, recent studies have yielded conflicting results.Methods.Herein, we systematically carried out a meta-analysis to assess the correlation between APC methylation and BC risk. Based on searches of the Cochrane Library, PubMed, Web of Science and Embase databases, the odds ratio (OR) with 95% confidence interval (CI) values were pooled and summarized.Results.A total of 31 articles involving 35 observational studies with 2,483 cases and 1,218 controls met the inclusion criteria. The results demonstrated that the frequency of APC methylation was significantly higher in BC cases than controls under a random effect model (OR= 8.92, 95% CI [5.12–15.52]). Subgroup analysis further confirmed the reliable results, regardless of the sample types detected, methylation detection methods applied and different regions included. Interestingly, our results also showed that the frequency of APC methylation was significantly lower in early-stage BC patients than late-stage ones (OR= 0.62, 95% CI [0.42–0.93]).Conclusion.APC methylation might play an indispensable role in the pathogenesis of BC and could be regarded as a potential biomarker for the diagnosis of BC.

Synthesis and Anticancer Potentials of Quinoline Analogues: A Review of Literature

2020 ◽  
Vol 17 ◽  
Author(s):  
Ajay Kumar ◽  
Salahuddin ◽  
Avijit Mazumder ◽  
Mohammad Shahar Yar ◽  
Rajnish Kumar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Colon Cancer ◽  
Pancreas Cancer ◽  
New Drugs ◽  
Cancer Breast ◽  
Privileged Structures ◽  
Approved Drugs ◽  
New Research ◽  
Cancer Côlon

Abstract: New drugs introduced on the market each year have privileged structures specifically for anticancer targets, of which quinoline-based analogues also play an important role. This review lit up quinoline and its derivatives, which have great potency against various cancer cells including prostate cancer, breast cancer, colon cancer, pancreas cancer and many more. This review describes the most likely process-scale synthetic approaches of quinoline and its derivatives having specific pharmacophore, for anticancer targets along. It is also described the undergoing development and recently approved drugs in tabular form. Quinoline moiety as privileged structural pharmacophore has most effective activity against different cancer cell lines like prostate cancer, breast cancer, stomach cancer, pancreas cancer, Colon cancer, CNS cancer and renal cancer. Because of this advantage, it has the potency to grow with new research works about the anticancer as well as enhancing the value of the investigative process in the field of medicinal chemistry by introducing new effective alignments of substituents. It can be used as lead compounds for further research in the subject of anticancer drug discovery.

Distribution of BRCA1/2 germline and somatic alterations across cancer type.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10590-10590
Author(s):  
Jingde Chen ◽  
Ming Quan ◽  
Zhengqing Yan ◽  
Shiqing Chen ◽  
Mei Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Ovarian Cancer ◽  
Endometrial Cancer ◽  
Genomic Dna ◽  
Pancreas Cancer ◽  
Clinical Laboratory ◽  
White Blood Cells ◽  
Cancer Type ◽  
Tumor Types

10590 Background: PARP inhibitors (e.g. Olaparib or niraparib) have been approved by FDA as a targeted therapy for many tumors harboring germline or somatic BRCA1/2 (g or sBRCA1/2), including ovarian cancer, prostate cancer, breast cancer and pancreases cancer. It is imperative to study the distribution of BRCA1/2 across cancer type. In this study, we aim to assess the landscape of BRCA1/2 alterations in solid tumors and evaluate the feasibility of circulating tumor DNA (ctDNA) tested by next-generation sequence (NGS) as a tool to detect BRCA1/2 alterations. Methods: For tissue specimen, genomic DNA from formalin fixed paraffin-embedded (FFPE) tumor specimens or fresh tumor tissues was used for sequence analysis. Genomic DNA (gDNA) from white blood cells was extracted using the QIAamp DNA Mini Kit (Qiagen). For ctDNA, cell-free DNA libraries were prepared using the KAPA Hyper Prep Kit following the manufacturer’s protocol. The captured libraries were loaded onto a NovaSeq 6000 platform (Illumina) for 100bp paired-end sequencing. The testing was performed in the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) -certified 3D Medicines Library. Results: A total of 27, 835 patients were tested using tumor tissue during Jan. 1th 2017 to June 1th 2020, including 43% (N = 12089) of non-small cell lung cancer, 19% (N = 5357) of colorectal cancer, 8% (N = 2181) of liver cancer, 6% (N = 1621) of gastric cancer, 5% (N = 1479) of biliary tract cancer, 4% (N = 1084) of kidney cancer, 4% (N = 1045) of pancreas cancer, 3% (N = 689) of breast cancer and 2% (N = 599) of ovarian cancer. Across all tumor types, the known or likely deleterious BRCA1/2 alterations were identified in 2147 (7.7%) patients. Ovarian cancer had the highest frequency of BRCA1/2 alteration (23.4%), followed by endometrial cancer (12.7%) and breast cancer (10.6%). BRCA1/2 alteration was found in 8.8% prostate cancer and 4.2% pancreas cancer respectively. Across all tumor types, the known or likely deleterious gBRCA1/2 alterations were identified in 369 (1.3%) patients. Notably, ovarian cancer had the highest frequency of gBRCA1/2 alteration (13.9%), followed by breast cancer (7%), prostate cancer (4.4%) and endometrial cancer (4.1%). No clear hotspot mutations and mutated codons were spread throughout g or sBRCA1/2 mutations. Additionally, among 15699 patients who suffered ctDNA sequencing, any known or likely deleterious sBRCA1/2 alterations were identified in 358 (2%) patients. Similar to the results of tissue sequencing, ovarian cancer had the highest frequency of sBRCA1/2 alteration (16.67%), followed by endometrial cancer (9.68%), prostate cancer (7.18%) and breast cancer (5.58%) in the blood cohort. Conclusions: BRCA1/2 alterations existed across tumor types and the landscape of g or sBRCA1/2 alterations varied according to cancer type. Furthermore, ctDNA can be used as a potential tool to detect BRCA1/2 alterations.

Sign in / Sign up

Export Citation Format

Share Document